Tempus

What they do

Tempus uses practical applications of artificial intelligence in healthcare to personalize cancer care. The company sequences genomic data and analyzes clinical notes, offering oncologists actionable insights to select the most effective therapies for individual cancer patients. In September 2026 Tempus announced FDA 510(k) clearance of Tempus ECG-MR, which reviews resting 12-lead ECGs from patients 65 or older at cardiovascular risk for signs of undiagnosed moderate or severe mitral regurgitation and flags them for further evaluation.

The record

Vertical

Oncology

Sub-segment

Precision medicine platform

Product type

Diagnostics

Stage

Public

Headquarters

Chicago, United States

Region

North America

Founded

2015

Total funding

$1.4B raised

Notable investors: T. Rowe Price, Baillie Gifford, Franklin Templeton, Novo Holdings.